Our study revealed not only the association between the levels of pCHK2T68 and oxaliplatin resistance in CRC but also the molecular mechanism by which CHK2 signalling participates in DNA damage repair, CHK2/PARP1 interaction, cell colony formation, and xenograft tumour growth in the presence of oxaliplatin. This evidence concerns the gene PARP1 and colorectal carcinoma.